RGD Reference Report - Thrombin activatable fibrinolysis inhibitor in Behcet's disease. - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

Thrombin activatable fibrinolysis inhibitor in Behcet's disease.

Authors: Donmez, A  Aksu, K  Celik, HA  Keser, G  Cagirgan, S  Omay, SB  Inal, V  Aydin, HH  Tombuloglu, M  Doganavsargil, E 
Citation: Donmez A, etal., Thromb Res. 2005;115(4):287-92.
RGD ID: 1598474
Pubmed: PMID:15668188   (View Abstract at PubMed)
DOI: DOI:10.1016/j.thromres.2004.09.010   (Journal Full-text)

INTRODUCTION: Thrombin activatable fibrinolysis inhibitor (TAFI) is a procarboxypeptidase downregulating plasmin formation, thereby causing a tendency for thrombosis development. Since, Behcet's disease (BD) is a systemic vasculitis, which is commonly complicated by arterial and venous thrombosis, we aimed to find out plasma TAFI levels in BD, compared with healthy controls. We also searched whether plasma TAFI levels were significantly different between Behcet's subgroups with and without thrombosis. MATERIALS AND METHODS: In this study, 105 BD patients (M/F: 64/41; mean age 36+/-1 years), followed up by Ege University Rheumatology Department were enrolled. The exclusion criteria were hemophilia, hyperlipidemia, diabetes mellitus, hepatic diseases renal failure, antiphospholipid positivity, oral contraceptive use and pregnancy. Age-and sex-matched healthy controls (n=53) were also included. Plasma TAFI levels were measured by ELISA. Since TAFI is also an acute-phase reactant, we also measured other inflammatory markers such as C-reactive protein (CRP). RESULTS: Plasma TAFI levels were significantly higher in Behcet's patients (91.1+/-7.4 ng/ml) compared with healthy controls (14.3+/-4.5 ng/ml) (P<0.001), but there were no significant difference between the subgroups with and without thrombosis. In BD, there was no correlation between plasma TAFI levels and CRP. CONCLUSIONS: Regardless of manifest thrombosis, plasma TAFI levels in BD were significantly higher than in healthy controls. High TAFI levels might possibly contribute to the thrombotic tendency in BD. Future studies investigating TAFI gene polymorphism and functional activity are clearly needed, to clarify the exact role of TAFI in Behcet's thrombosis.

RGD Manual Disease Annotations    Click to see Annotation Detail View
TermQualifierEvidenceWithReferenceNotesSourceOriginal Reference(s)
Behcet's disease  IEP 1598474 RGD 
Behcet's disease  ISOCPB2 (Homo sapiens)1598474; 1598474 RGD 

Objects Annotated

Genes (Rattus norvegicus)
Cpb2  (carboxypeptidase B2)

Genes (Mus musculus)
Cpb2  (carboxypeptidase B2)

Genes (Homo sapiens)
CPB2  (carboxypeptidase B2)


Additional Information